<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'>
<creators>
<creator>
<creatorName>Caraman, N.C.</creatorName>
<affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation>
</creator>
</creators>
<titles>
<title xml:lang='ro'>Preparatele antihipertensive la pacienții cu diabet zaharat</title>
</titles>
<publisher>Instrumentul Bibliometric National</publisher>
<publicationYear>2023</publicationYear>
<relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'>978-9975-50-306-8.</relatedIdentifier>
<subjects>
<subject>hypertension</subject>
<subject>diabetes mellitus</subject>
<subject>antihypertensive drugs</subject>
<subject>antihy-pertensive effect</subject>
<subject>metabolic disturbances</subject>
<subject schemeURI='http://udcdata.info/' subjectScheme='UDC'>616.379:616.12</subject>
</subjects>
<dates>
<date dateType='Issued'>2023</date>
</dates>
<resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType>
<descriptions>
<description xml:lang='en' descriptionType='Abstract'><p>Hypertension and diabetes are components of metabolic syndrome. The coexistence of these two diseases is associated with increased risk of cardio-vascular events. The microvascular and macrovascular complications are signi-ficantly more common unfavourable cardiovascular events. The first line of anti-hypertensive drug classes includ angiotensin-converting enzyme inhibitors, an-giotensin receptor blockers, calcium channel blockers, thiazide-like diuretics, mi-neralocorticoid receptor antagonists, and beta-blockers. The second-line anti-hypertensive drugs include &alpha;-blockers, renin inhibitors, loop diuretics, substan-ces affecting the central nervous system (methyldopa, clonidine), and vasodila-tors. The exact choice of hypotensive drugs depends on various factors: comorbi-dities, estimated glomerular filtration rate, side effects and ethnicity.</p></description>
</descriptions>
<formats>
<format>application/pdf</format>
</formats>
</resource>